Kornimate/medical-research-clean huggingface dataset:
sucrose analgesia for the reduction of pain during retinopathy of prematurity screening

Conditions: Retinopathy of Prematurity

Summary: retinopathy of prematurity (rop) screening is one of many potentially painful diagnostic and therapeutic procedures performed routinely on preterm infants in the neonatal intensive care unit. therefore strategies for stress reduction and pain management are essential to promote growth and development and minimize long-term sequelae. procedural analgesia should include concepts of developmental care, non nutritive suck (nns), pharmacological and non-pharmacological agents. sucrose is thought to stimulate the body's activation of lingual sweet taste receptors and release of endogenous opioids, when combined with nns, non-opioid mechanisms are also activated. the administration of sucrose or the combination of sucrose and non-nutritive sucking is one of the most frequently studied non-pharmacological interventions for relief of pain in neonates and oral sucrose has been shown to be an effective and safe therapy for common neonatal procedures such as heal lance, blood-letting and venepuncture. there is conflicting evidence on the benefit of sucrose in rop screening. therefore the purpose of this study is to determine the efficacy of sucrose combined with nns as a potential regime for reduction of pain associated with retinopathy of prematurity screening.


Eligibility criteria:
inclusion criteria: * \< 1500 grams * \< 32 weeks exclusion criteria: * requiring mechanical ventilation excluding continuous positive pressure ventilation (cpap), sedation * infants where consent to participate was not obtained

Keywords: rop sucrose pain
ventilatory muscle training by breath-stacking in healthy youngsters

Conditions: Muscle Weakness

Summary: in several diseases in which muscle weakness is a determining factor for morbidity and mortality, inspiratory muscle training has been shown to be useful in improving the function of ventilatory muscles, delaying or minimizing the development of complications due to the reduction of inspiratory muscle strength. the breath-stacking technique emerges as an easily applicable alternative, and it can be used in poorly collaborative patients. the technique described in the literature aims to increase pulmonary volumes. this gain occurs with the coupling of a silicone mask on the patient's face, a unidirectional valve and with the expiratory branch occluded. thus, inspirations occur sequentially in this medium, generating pulmonary hyperinflation and increasing the contractility power of the expiratory muscles, which are fundamental for coughing. this hyperinflation also improves the peripheral air distribution in the lungs by increasing intrathoracic pressure. the objective of this study is to evaluate the effect of the breath-stacking (bs) technique on the ventilatory muscle strength of young and healthy individuals.

initially, participants will be submitted to a learning session on the evaluation of ventilatory muscle strength and the breath-stacking technique. between 24-72 hours after the learning, the evaluation of the muscular muscular strength will be performed through the maximal inspiratory pressure (mip) and the maximum expiratory pressure (mep). pi max will be measured from a maximum expiration; while pe max will be measured from a maximum inspiration, using a digital manovacuometer (mvd 300®)

Eligibility criteria:
inclusion criteria: * no signs and symptoms of pulmonary diseases, normal ventilatory muscle strength and agreement to participate and sign the informed consent form. exclusion criteria: * presenting neuromuscular diseases, claustrophobia, ruptured eardrum, history of spontaneous pneumothorax and playing wind instruments or being a singer. sample loss will be considered as non-attendance at all training sessions.
cognitive behavioral therapy for sleep and circadian disturbances (cbt-i) in treatment-resistant schizophrenia

Conditions: Treatment-refractory Schizophrenia; Treatment-resistant Schizophrenia

Summary: using a randomized controlled design, the project aims to test if cognitive behavioral therapy interventions specifically targeting sleep disorders can significantly lessen the burden of the disrupted sleep in patients with treatment resistant schizophrenia (trs) and by proxy lead to a reduction in psychotic symptoms and improvement in quality of life. we are including treatment-resistant patients with schizophrenia other nonorganic and chronic psychoses and in addition meeting the criteria of a sleep or circadian disorder. included patients will be block randomized to either 8-10 sessions of cbt-i (active treatment) with a specific focus on sleep or 8-10 sessions of regularcbt with a specific focus on patients' psychopathology (treatment as usual) approx.1 session/week. after 12 weeks the full battery of assessments will be repeated forboth groups. primary analyses will be to identify group-difference in changes using repeated measure anova.


Eligibility criteria:
inclusion criteria: * diagnosed with icd-10 schizophrenia (df20), chronic paranoid psychosis (df22), schizo-affective disorder (df25) or other non-organic psychosis (df28-df29) * treatment resistance according to trrip criteria * sleeping difficulties (minimum duration 3 months) * isi score \>14 * stable psychopharmacological treatment the last month * only legal competent patient can participant exclusion criteria: * psychiatric admission last six months (more than 1 week or resulted in significant changes in psychopharmacological treatment) * substance abuse to a degree that will interfere with participation. * diagnoses of sleep apnea/cpap use

Keywords: cognitive cbt therapy insomnia polysomnography
the effects of core stability training in chronic stroke patients

Conditions: Stroke

Summary: the purpose of this study is to assess effects of core stability training on functional ability, balance, gait, motor functions, quality of lite and core muscle thickness of chronic stroke patients.

after being informed about the study all the patients giving written informed consent were assessed. at the beginning the eligible patients were randomized into two groups: core stability and conventional therapy group. the therapy programs were performed 5 times a week for 45 min over a period of 3 weeks. patients were assessed twice: before and after treatment.

Eligibility criteria:
inclusion criteria: * first onset * stroke duration from 6 months to 2 years * with ability to cooperate * independent ambulation or ambulation with assistive device exclusion criteria: * uncooperative * neglect syndrome * surgical history of abdominal and hip region * drugs that affect neuromuscular control * other neurological disorders * serious diseases, unstable medical condition * bmi ≥ 35
a first-in-human study using bdc-1001 as a single agent and in combination with nivolumab in advanced her2-expressing solid tumors

Conditions: HER2-positive Solid Tumors; HER2-positive Breast Cancer; HER2-positive Colorectal Cancer; HER2-positive Gastroesophageal Cancer; HER2-positive Endometrial Cancer

Summary: a first-in-human study using bdc-1001 as a single agent and in combination with nivolumab in her2 expressing advanced malignancies

this study has four parts. part 1 is a dose escalation of bdc-1001 as a single agent to determine the maximum tolerated dose (mtd), recommended phase 2 dose (rp2d), or maximum protocol dose (mpd) recommended for part 3. in part 3, the selected dose will be administered as monotherapy to patients with selected advanced malignancies. part 2 is a dose escalation of bdc-1001 in combination with nivolumab to determine the maximum tolerated dose (mtd), recommended phase 2 dose (rp2d), or maximum protocol dose (mpd) recommended for part 4. in part 4, the selected dose will be administered in combination with nivolumab to patients with selected advanced malignancies. bolt amended the protocol to transition any subjects still receiving bdc-1001 to continue receiving bdc-1001 in the maintenance phase. subjects remaining on bdc-1001 will continue to receive bdc-1001 until a criterion for discontinuation has been met.

Eligibility criteria:
key inclusion criteria: * patient must have an advanced solid tumor with documented her2-protein expression or gene amplification for which approved therapies have been exhausted or are not clinically indicated. * measurable disease as determined by recist v.1.1. * eastern cooperative oncology group (ecog) performance status of 0 or 1. * tumor tissue (archival or collected prior to the study start) available for exploratory biomarker evaluation. key exclusion criteria: * history of severe hypersensitivity to any ingredient of the study drug(s), including trastuzumab or other monoclonal antibody. * previous treatment with a tlr 7, tlr 8 or a tlr 7/8 agonist. * impaired cardiac function or history of clinically significant cardiac disease * human immunodeficiency virus (hiv) infection, active hepatitis b infection, or hepatitis c infection. * active sars-cov-2 infection * untreated central nervous system (cns), epidural tumor or metastasis, or brain metastasis. other protocol defined inclusion/exclusion criteria may apply.

Keywords: her2 erbb2 immunotherapy gastric cancer gastroesophageal junction breast cancer stomach cancer colorectal cancer gastrointestinal cancer non-small cell lung cancer biliary tract cancer head and neck cancer urothelial cancer endometrial cancer tlr7/8 agonist
phase ii study evaluating ono-4053 and cetirizine in subjects with seasonal allergic rhinitis

Conditions: Seasonal Allergic Rhinitis

Summary: the purpose of this study is to investigate if ono-4053 relieves symptoms of allergic rhinitis in seasonal allergic rhinitis subjects exposed to pollen under controlled conditions.

the purpose of this study is to investigate if ono-4053 will impact allergic rhinitis symptoms in subjects with seasonal allergic rhinitis when they are exposed to pollen administered at a fixed rate in an inhalation exposure chamber compared to the standard treatment cetirizine 10mg under the same conditions.

Eligibility criteria:
inclusion criteria: * the subject is aged between 18 and 65 years inclusive, and healthy with the exception of allergic rhinitis or mild asthma that does not require treatment and has provided written informed consent, which signifies an agreement to enter the study and comply with the restrictions and requirements listed in the informed consent form. * the subject exhibits a moderate to severe response to grass pollen grains in the allergen challenge chamber at screening. exclusion criteria: * the subject on examination is found to have nasal structural abnormalities or nasal polyps; a history of frequent nose bleeds, nasal biopsy, nasal trauma or nasal surgery. * pregnant or breast-feeding females.
effect of bupivacaine liposome anterior serratus deep block on chronic pain after breast cancer surgery: a randomized controlled study

Conditions: Breast Cancer Patients With Chronic Pain After Surgery

Summary: this study aims to investigate the effect and influence of liposome bupivacaine anterior serrat plane block on postoperative chronic pain in breast cancer patients, evaluate the therapeutic effect of liposome bupivacaine in postoperative chronic pain, and provide a new method for patients with postoperative chronic pain.


Eligibility criteria:
inclusion criteria: * adult patients (aged ≥18 years) who are scheduled to undergo unilateral modified radical breast cancer surgery exclusion criteria: * 1. patients with coagulation dysfunction 2. there are infected patients at the puncture site 3. for patients allergic to any trial drug 4. patients who take painkillers within 48 hours before surgery 5. severe cardiopulmonary insufficiency, such as ef\< 40%, fevc \< 50% expected; uncontrolled hypertension; 6. refuse to perform nerve block puncture 7. mental disorders, epilepsy history; 8. unable to give informed consent or are participating in other clinical trials.
performance of toric silicone hydrogel contact lenses

Conditions: Astigmatism; Myopia

Summary: the purpose of this study was to evaluate the clinical performance and subjective lens handling (insertion and removal) of two toric silicone hydrogel contact lenses after one month of daily wear each.

this was a prospective, randomized, double masked, bilateral, crossover study. participants were expected to attend 6 scheduled visits over a period of approximately 2 months.

Eligibility criteria:
inclusion criteria: a person is eligible for inclusion in the study if he/she: * is between 18 and 40 years of age (inclusive) * has had a self-reported visual exam in the last two years * is an adapted soft contact lens wearer * is not a habitual wearer of either study lens * has a contact lens spherical prescription between +4.00 to - 10.00 (inclusive). best corrected visual acuity of 20/30 or better in either eye * have contact lens prescription of no less than -0.75d of astigmatism and no more than -2.25 d in both eyes. * can achieve best corrected spectacle distance visual acuity of 20/25 (0.10 logmar) or better in each eye. * can achieve a distance visual acuity of 20/30 (0.18 logmar) or better in each eye with the study contact lenses. * has clear corneas and no active ocular disease * has read, understood and signed the information consent letter. * patient contact lens refraction should fit within the available parameters of the study lenses. * is willing to comply with the wear schedule (at least 5 days per week, \> 8 hours/day assuming there are no contraindications for doing so). * is willing to comply with the visit schedule exclusion criteria: a person will be excluded from the study if he/she: * a person was excluded from the study if he/she: * has a cl prescription outside the range of the available parameters of the study lenses. * has a spectacle cylinder less than -0.75d or more than -2.50 d of cylinder in either eye. * has a history of not achieving comfortable cl wear (5 days per week; \> 8 hours/day) * has contact lens best corrected distance vision worse than 20/25 (0.10 logmar) in either eye. * presence of clinically significant (grade 2-4) anterior segment abnormalities * presence of ocular or systemic disease or need of medications which might interfere with contact lens wear. * slit lamp findings that would contraindicate contact lens wear such as: * pathological dry eye or associated findings * pterygium, pinguecula, or corneal scars within the visual axis * neovascularization \> 0.75 mm in from of the limbus * giant papillary conjunctivitis (gcp) worse than grade 1 * anterior uveitis or iritis (past or present) * seborrheic eczema, seborrheic conjunctivitis * history of corneal ulcers or fungal infections * poor personal hygiene * has a known history of corneal hypoesthesia (reduced corneal sensitivity) * has aphakia, keratoconus or a highly irregular cornea. * has presbyopia or has dependence on spectacles for near work over the contact lenses. * has undergone corneal refractive surgery. * is participating in any other type of eye related clinical or research study.
expanded access use of incb052793 to treat a single patient with myelofibrosis


Summary: expanded access use of incb052793 to treat a single patient with myelofibrosis.


Eligibility criteria:
inclusion criteria: - exclusion criteria: -
the effectiveness of a protocol for muscular foot strengthening on a capacity to control the deformation of the dot plantar medial

Conditions: Foot Diseases

Summary: the human foot allows to perform several functions, rather than providing a static support for the body, the foot acts dynamically in walking and movement of the body, requiring adequate biomechanics responsible for maintenance and posture of the body and harmonic distribution of plantar pressure. one of the most important structures for this control is the medial plantar vault (mpa), an important structure in the absorption of impact and essential for the function foot. the deformation of the mpa in the gait support phase absorbs the energy and propels the limb, to perform this biomechanical function the mpa must stable from the anatomical point of view, which is conferred by the bone architecture and but also by the performance of the intrinsic and extrinsic musculature of the feet. the fall of the mpa, decreases the stability of the foot, limits its biomechanical function, besides being a risk factor for the development of pathologies such as: tendinopathy of the calcaneus tendon and plantar fasciitis. various intrinsic muscles and extrinsic have the function of stabilizing the foot and the mpa, being the main extrinsic muscles: the posterior tibial, the flexor long of the hallux and the fingers. the muscles when activated increase the height and decrease the length of the mpa. several methods are used to evaluate alm, such as (an), feiss line (lf) and mpa angle (mpah), in addition to the baropodometry, which is used to evaluate dysfunctions in the feet, with the principle of map the pressure of the plantar surface in a static and dynamic way. based in this information, this study aims to evaluate the influence of the strengthening of the intrinsic and extrinsic muscles of the feet, for the of mpa in asymptomatic patients.


Eligibility criteria:
inclusion criteria: * individuals between the ages of 18 and 40, * seeders (do not practice physical activity regularly) * no previous injuries to the feet and ankles, * 12 months without lesions in lower members, * without deformities in apm, * such as, rigid planar foot * no history of neurological changes exclusion criteria: * individuals who practice physical activities regularly, * history of pain in the feet, * have suffered fractures in the lower limbs, * muscular and articular lesions of lower members in 12 months, - * flat foot, * valgus of calcaneus above 10º * history of neurological changes or surgical procedure performed on lower limbs
effect of exercises on kinesiophobia, and other symptoms related to osteoporosis

Conditions: Osteoporosis

Summary: aim: investigating the effects of clinical pilates exercise on kinesiophobia, pain, functional status and quality of life of the patients diagnosed with osteoporosis. method: 47 patients were assessed and randomly divided into 2 groups. exercise group patients joined exercise program regularly that was held 3 times a week, 1 hour a day, during 6 weeks with physiotherapist. control group patients continued their normal daily lives without any exercise. after 7 patients quit the study for various reasons, 40 women with primary osteoporosis (control group n=20, exercise group n= 20), completed the study and were assessed at the beginning and at the end of 6 weeks. as assesment' measurements tampa kinesiophobia scale (tks), visual analog scale (vas), short form mcgill (sf-mcgill), pain disability index (pdi), oswestry disability index (odi), berg balance test (bbt), timed up- go test (tug), chair sit-stand test (csst), chair sit and reach test (csrt), back scratch test (bst), quality of life questionnaire european foundation for osteoporosis (qualeffo-41), hospital anxiety and depression scale (hads), satisfaction with life scale (sls) and health assesment questionnaire (haq) were performed.


Eligibility criteria:
inclusion criteria: * woman diagnosed with osteoporosis between the ages 50-75 within the last year exclusion criteria * history of fractures * joint replacements or fixation of the joints at the lower extremities or the spine * any neurological or muscle diseases * inability to continuously attend the exercise program * any secondary diseases resulting in decreased mobility or functional status * visual, hearing or mental problems that could prevent communication

Keywords: osteoporosis clinic pilates exercise kinesiophobia pain
ultrasound guided erector spinae plane block vs external oblique intercostal plane block for nephrectomy

Conditions: Post Operative Pain

Summary: the patients will be randomly allocated into two equal groups using a computer program. group a: will receive u s guided external oblique intercostal block after induction. group b: patients will receive us guided erector spine block after induction.

patients will be premedicated with iv midazolam (0.05 mg/kg). under standard monitoring including electrocardiography, non-invasive blood pressure, and pulse oximetry. general anesthesia will be induced with fentanyl (1-2 μg/kg), propofol (2-3 mg/kg), and atracurium (0.5-0.8 mg/kg). pressure controlled volume guarantee ventilation mode will be used to maintain o2 saturation above 98%. anesthesia will be maintained with isoflurane 1.2 minimum alveolar concentration inhalation

Eligibility criteria:
inclusion criteria: * eligible patients will be older than 21 years old with american society of anesthesiology asa physical status i\& ii\&iii scheduled for elective (subcostal) nephrectomy exclusion criteria: * patients who are: * uncooperative. * having allergy to any of the study drugs. * known abuse of alcohol or medication. * having local infection at the site of injection or systemic infection. * pregnancy. * with coagulation disorders or on anticoagulation therapy.
changes in the carbon dioxide content in the body during a simulated avalanche burial with and without the use of a breathing tube system.

Conditions: Avalanche Burial

Summary: every year, around 100 people die in avalanches in the alps. many of these accidents occur during winter sports. in most cases, the victims suffocate under the snow after the avalanche has come to a standstill. a key survival factor here is the time it takes to be rescued. if a buried victim is rescued within 15 minutes, the probability of survival is over 90%. after 35 minutes, however, this drops drastically to just 30%. a modern avalanche rescue system, such as the avalung-device, could extend the survival time. the system directs the exhaled air via a tube to the back of the buried person so that no toxic co2 concentrations build up in the available breathing cavity. it is also intended to prevent the formation of an "ice mask", which can impair the release of oxygen from the snow. this study investigates whether the avalung system can extend the survival time in the event of burial. the aim is to test the effects of such a breathing tube system. the oxygen and carbon dioxide levels of the test subjects are measured while they are buried in a simulated avalanche - once with and once without the avalung system. in addition, it is investigated how long it takes before the buried subjects have to stop the examination, for example due to shortness of breath or deteriorating respiratory gases in the blood. test setup: the test subjects lie on their backs with their heads and chests buried under snow. during the test phase, various parameters are continuously monitored, such as the breathing rate and the co2 concentration in the blood. a comparative study is carried out: once with a functioning rescue system, and once with a manipulated (non-functioning) system. expected benefit: the results of this study should contribute to a better understanding of the effectiveness of avalanche rescue systems and thus increase the chances of survival of avalanche victims in the future. this is particularly important today, as the number of winter sports enthusiasts and the number of avalanches triggered by them is constantly increasing.


Eligibility criteria:
inclusion criteria: * adults over 18 * able to consent exclusion criteria: * anamnestic evidence of previous pulmonary or cardiac disease * known neuromuscular diseases * thoracic deformities * acute respiratory infections * in women: pregnancy (excluded by history and urine test) * age over 60 years * presence of claustrophobia

Keywords: aapd artificial air-pocket device